These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25582974)

  • 1. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome.
    Harmatz PR; Mengel KE; Giugliani R; Valayannopoulos V; Lin SP; Parini R; Guffon N; Burton BK; Hendriksz CJ; Mitchell JJ; Martins AM; Jones SA; Guelbert N; Vellodi A; Wijburg FA; Yang K; Slasor P; Decker C
    Mol Genet Metab; 2015 Feb; 114(2):186-94. PubMed ID: 25582974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
    Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
    Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
    Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
    Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
    Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
    Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects.
    Harmatz P; Mengel KE; Giugliani R; Valayannopoulos V; Lin SP; Parini R; Guffon N; Burton BK; Hendriksz CJ; Mitchell J; Martins A; Jones S; Guelbert N; Vellodi A; Hollak C; Slasor P; Decker C
    Mol Genet Metab; 2013 May; 109(1):54-61. PubMed ID: 23452954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome.
    Schrover R; Evans K; Giugliani R; Noble I; Bhattacharya K
    Orphanet J Rare Dis; 2017 Apr; 12(1):78. PubMed ID: 28441951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.
    Hendriksz CJ; Berger KI; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Matousek R; Jurecki E; Decker C; Harmatz PR
    J Inherit Metab Dis; 2016 Nov; 39(6):839-847. PubMed ID: 27553181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
    Hendriksz CJ; Burton B; Fleming TR; Harmatz P; Hughes D; Jones SA; Lin SP; Mengel E; Scarpa M; Valayannopoulos V; Giugliani R; ; Slasor P; Lounsbury D; Dummer W
    J Inherit Metab Dis; 2014 Nov; 37(6):979-90. PubMed ID: 24810369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study.
    Burton BK; Berger KI; Lewis GD; Tarnopolsky M; Treadwell M; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Genter F; Shaywitz AJ; Harmatz P
    Am J Med Genet A; 2015 Oct; 167A(10):2272-81. PubMed ID: 26069231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study.
    Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Mitchell JJ; Burton BK; Guelbert N; Stewart FJ; Hughes DA; Matousek R; Hawley SM; Decker C; Harmatz PR
    Mol Genet Metab; 2018 Feb; 123(2):127-134. PubMed ID: 29248359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational study.
    Moisan L; Iannuzzi D; Maranda B; Campeau PM; Mitchell JJ
    Orphanet J Rare Dis; 2020 Sep; 15(1):270. PubMed ID: 32993725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
    Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
    Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
    Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
    Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a Respiratory Training Program Using Wind Instruments on Cardiopulmonary Function, Endurance, and Quality of Life of Elderly Women.
    Kim BS; Kim JH; Park SH; Seo HS; Lee HS; Lee MM
    Med Sci Monit; 2018 Jul; 24():5271-5278. PubMed ID: 30056459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa.
    Mitchell JJ; Burton BK; Bober MB; Campeau PM; Cohen S; Dosenovic S; Ellaway C; Bhattacharya K; Guffon N; Hinds D; Lail A; Lin SP; Magner M; Raiman J; Schwartz-Sagi L; Stepien KM
    Mol Genet Metab; 2022; 137(1-2):164-172. PubMed ID: 36087504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
    Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
    Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined inspiratory and expiratory muscle training program improves respiratory muscle strength and fatigue in multiple sclerosis.
    Ray AD; Udhoji S; Mashtare TL; Fisher NM
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1964-70. PubMed ID: 23714277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa.
    Berger KI; Burton BK; Lewis GD; Tarnopolsky M; Harmatz PR; Mitchell JJ; Muschol N; Jones SA; Sutton VR; Pastores GM; Lau H; Sparkes R; Shaywitz AJ
    JIMD Rep; 2018; 42():9-17. PubMed ID: 29159458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.